A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
Public ClinicalTrials.gov record NCT02174861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334
Study identification
- NCT ID
- NCT02174861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 609 participants
Conditions and interventions
Conditions
Interventions
- Erenumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 66 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2014
- Primary completion
- May 25, 2017
- Completion
- May 25, 2017
- Last update posted
- Oct 11, 2022
2014 – 2017
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Palo Alto | California | 94304 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Sherman Oaks | California | 91403 | — |
| Research Site | Stamford | Connecticut | 06905 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Orlando | Florida | 32801 | — |
| Research Site | Palm Beach Gardens | Florida | 33410 | — |
| Research Site | West Palm Beach | Florida | 33407 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Decatur | Georgia | 30033 | — |
| Research Site | Indianapolis | Indiana | 46256 | — |
| Research Site | Pikesville | Maryland | 21208 | — |
| Research Site | Watertown | Massachusetts | 02472 | — |
| Research Site | Worcester | Massachusetts | 01605 | — |
| Research Site | Ann Arbor | Michigan | 48104 | — |
| Research Site | Springfield | Missouri | 65807 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | Reno | Nevada | 89502 | — |
| Research Site | Amherst | New York | 14226 | — |
| Research Site | Greensboro | North Carolina | 27405 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Austin | Texas | 78731 | — |
| Research Site | Dallas | Texas | 75214 | — |
| Research Site | Dallas | Texas | 75231 | — |
| Research Site | Virginia Beach | Virginia | 23454 | — |
| Research Site | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02174861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02174861 live on ClinicalTrials.gov.